357 related articles for article (PubMed ID: 1591724)
21. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
22. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line.
Saburi Y; Nakagawa M; Ono M; Sakai M; Muramatsu M; Kohno K; Kuwano M
Cancer Res; 1989 Dec; 49(24 Pt 1):7020-5. PubMed ID: 2479474
[TBL] [Abstract][Full Text] [Related]
25. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
26. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
27. Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation.
De Pooter CM; Scalliet PG; Elst HJ; Huybrechts JJ; Gheuens EE; Van Oosterom AT; Fichtinger-Schepman AM; De Bruijn EA
Cancer Res; 1991 Sep; 51(17):4523-7. PubMed ID: 1873796
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
30. Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Dempke WC; Hosking LK; Hill BT
Semin Oncol; 1992 Apr; 19(2 Suppl 3):66-72. PubMed ID: 1557659
[TBL] [Abstract][Full Text] [Related]
31. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia.
Mansouri A; Henle KJ; Benson AM; Moss AJ; Nagle WA
Cancer Res; 1989 May; 49(10):2674-8. PubMed ID: 2713851
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
34. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
35. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
36. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
37. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine.
Scanlon KJ; Kashani-Sabet M; Sowers LC
Cancer Commun; 1989; 1(4):269-75. PubMed ID: 2534792
[TBL] [Abstract][Full Text] [Related]
40. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line.
Hong WS; Son YS
Anticancer Res; 1996; 16(5A):3031-6. PubMed ID: 8917423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
